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vs. 100.1 mg. Differences in doses were tested using lin-
ear models with a normal error distribution. Differences
in frequency of use were tested using categorical data
models (models of population homogeneity). Statistical
significance (p  .05) was achieved only on the frequency
with which nefazodone is used to treat PTSD and depres-
sion, as compared to other drugs. Statistical significance
of dose differences was not achieved due to a large varia-
tion in dosing of each drug.
CONCLUSION: At this medical center, nefazodone is
used significantly more frequently for PTSD than the SS-
RIs. Since severity of diagnosis and outcomes were not
included in this study, no conclusion can be made regard-
ing differences in efficacy between the groups. A poten-
tial pharmacotherapeutic advantage of nefazodone as a
treatment for PTSD is its proposed efficacy in treating
disorders commonly comorbid with PTSD, such as de-
pression, panic, anxiety, agitation, and sleep disturbance.
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OBJECTIVES: With increasing medical costs, the health
of schizophrenia caregivers cannot be ignored. This re-
search evaluated health-care resource use among care-
givers of people with varying severities of schizophrenia.
METHODS: In June 2000, 376 schizophrenia caregivers
from national support groups completed self-administered
questionnaires. They reported whether they were hospi-
talized (17%), visited the ER (19%), or had physicians’
appointments (48%) in the past six months. Caregivers
rated schizophrenia severity by reporting how often (on a
scale from 0 to 4) their patient experienced 23 problems.
Scores were then computed as the overall mean. Logistic
regression was used to control for other variables that
could confound resource use: caregivers’ demographics as
well as overall mental and physical health; patients’ demo-
graphics; time with schizophrenia, and antipsychotic use.
RESULTS: Controlling for these confounders, caregivers
of people with severe schizophrenia were about three times
more likely to have been hospitalized (OR  2.8, p 
.001) or to have visited an ER (OR  3.1, p  .001) in the
previous six months. The effect of severity on the number
of physician visits was not significant (p  0.798).
CONCLUSIONS: Medications and other strategies that
help control patients’ severity, or that help maintain peo-
ple at lower severity may reduce caregivers’ use of hospi-
tals and emergency rooms and ultimately lower the over-
all costs associated with treating schizophrenia.
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OBJECTIVES: Caregivers’ mental health, and the effect
of schizophrenia severity, may be critical to patients’
quality of care. This research therefore evaluates how the
symptoms of schizophrenia affect the mental well being
of those providing informal patient care.
METHODS: In June 2000, 376 schizophrenia caregivers
from national support groups completed self-adminis-
tered questionnaires. Mental well being was measured us-
ing the SF-12. Schizophrenia symptoms were evaluated as
a four-level variable: high negative/high positive (35%);
high negative/low positive (17%); low negative/high posi-
tive (10%); low negative/low positive (38%). To control
for confounders to caregivers’ well being—caregivers’ de-
mographics and involvement, and patients’ demographics
and time with schizophrenia—a linear regression model
was used.
RESULTS: The mean SF-12 score was 48.7 (SD 
 10.6).
In bivariate, chi-squared analysis, caregivers’ mental well
being decreased as schizophrenia symptoms increased
(p  .001). Controlling for confounders, symptom sever-
ity remained significant. Caregivers of people with low
positive and negative symptoms had average SF-12 scores
six points higher than those caring for people with high
symptoms (p  .001). Even caregivers of people with
only high positive symptoms scored about five points
higher (p  0.015).
CONCLUSIONS: Caregivers of people with high nega-
tive symptoms did not differ from those with both high
negative and positive symptoms (p  0.616). Medica-
tions and strategies that help control patients’ symptoms,
especially negative symptoms, can also help caregivers
experience more positive well being.
RESPIRATORY DISORDERS
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OBJECTIVE: To evaluate variations in work-loss esti-
mates by phone interview method. 
METHODS: In phone interviews, total work loss estimates
were based on three domains: missed workdays; missed
hours, and reduced productivity on days at work while not
feeling well. Three different phone interviews were devel-
oped. Version 1 (V1) included a lengthy direct assessment of
work loss. Version 2 (V2) was an abridged version of V1.
Version 3 (V3) included a brief indirect assessment of work
loss. Two recall periods at one week and at four weeks were
also tested. Combining the three versions and the two recall
periods yielded six different interviews. A convenience sam-
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ple (n  20,088) of adult residents from the Baltimore, MD
and Chicago, IL areas was contacted by phone, of whom
7,691 met occupation eligibility criteria. Respondents were
randomized to one of the six interviews at the time of con-
tact. Interviews were compared on the basis of estimates of
work loss and variation in estimates of work loss associated
with recall period and version.
RESULTS: Interviews varied in average length from 9.2
minutes (V3) to 15.1 minutes (V1). The participation rate
(66%) did not vary with the version. Estimates of work
loss varied with recall period and version. The mean total
hours/week of lost productive work time was lower for
interviews using a four-week compared to a one-week re-
call period. V3 of the interviews was the most discrim-
inating for illness-related work-loss estimates. For ex-
ample, individuals with allergic rhinitis (AR) reported
significantly more lost productive time at work due to
not feeling well compared to controls and a stronger rela-
tion between severity of AR and work loss.
CONCLUSION: Variation in relatively short recall peri-
ods influences estimates of work loss. Interview version 3
required the least time to administer and was the most
discriminating in terms of work-loss estimates by illness
status and illness severity.
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OBJECTIVE: To collect information on knowledge of
asthma by patients (pts), on its management and outcomes.
METHODS: multi-center, cross-sectional survey. Patients
(pts) were administered a questionnaire derived from the
one used in the survey “Asthma Insights & Reality in Eu-
rope” (A.I.R.E.). The questionnaire was adapted for ad-
ministration during a visit, instead of by phone as done
during A.I.R.E.
RESULTS: During the second half of 2000, 105 pneu-
mologists administered the questionnaire to 1017 asth-
matic pts (972 fully evaluable). Urban population repre-
sented 53% of the sample, males were 44%, mean age
was 44 years, and 35% suffered from seasonal asthma.
Relatives suffering from asthma were reported by 39% of
pts. Most pts (80%) believed that the number of Italian
asthmatics had increased during the last decade. Those
who rated their health status as at least good were 60%.
Fifty three percent thought that their asthma was better
today than 10 years ago. During the last 12 months, se-
vere symptoms were reported by 44% of pts, 11% of pts
spent at least one night in hospital, 16% reported access-
ing an emergency department, and 34% had an unsched-
uled visit. During the last four weeks, asthma was re-
ported as very good/good by 53%. In the same time,
72% of pts reported symptoms of various severity, and
40% of pts had night awakening. The peak flow meter
was known by 54% of pts. Thirty two percent of pts
owned one, but more than 50% of pts did not use it or
used it only when symptoms appeared. Half of pts under-
went lung functionality tests during the last 12 months.
CONCLUSION: Our data suggest that asthma manage-
ment does not usually fit the GINA guidelines. Health
status reported by pts does not always correspond with
symptom severity assessed by doctors. The hospitaliza-
tion rate and unscheduled visits due to asthma seem to be
higher than expected.
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OBJECTIVES: To determine the cost-effectiveness of ba-
sic monotherapy for bronchial asthma in children with
nedocromil sodium with or without specific immunotro-
pic therapy (SIT).
METHODS: Criteria for effectiveness were the number
of asymptomatic days per year and a complex estimation
by A. Zemskov (1997) which includes dynamics, clinical
and immunochemical markers of allergic inflammation.
Direct and indirect costs were calculated using data from
patient diaries with daily recording of medication and
medical care. We observed 100 children with moderately
severe asthma. The first group received monotherapy
with nedocromil sodium. The second group received
nedocromil sodium with SIT domestic allergens.
RESULTS: The study revealed that use of nedocromil so-
dium in 84.0 
 4.23% of the children provided 327.24 

1.04 asymptomatic days per year. The cost of one asymp-
tomatic day was 15.44 
 0.26 rubles. The use of SIT in
the first year of treatment improved the control of
asthma, and the number of asymptomatic days per year
was 333,8 
 1,01. The cost of one asymptomatic day in
this group is 12,04 
 0,28 rubles. Incremental cost-effec-
tiveness ratio in group with SIT was 171,71. This com-
plex analysis of the index with determination of clinico-
immunological effectiveness was 944,41.
CONCLUSIONS: Our investigation showed that SIT in
children with moderately severe asthma improved the ef-
fectiveness of basic therapy and reduced expenditures.
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